$3.67-3.8%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed November 12, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Profit | -$64.6M | -$1.8M | -3,498.77% |
| Profit per share | -$4.52 | -$0.38 | -1,089.47% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Azora Therapeutics, Inc. reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“With our transition to Nasdaq, Azora is well positioned for success to bring AhR biology to people living with ulcerative colitis,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177 is a prodrug of the active ingredient, indirubin, a potent AhR agonist derived from indigo naturalis, a botanical extract that has been evaluated in clinical studies in patients with ulcerative colitis but has not been approved by the U.S. Food and Drug Administration. AT177’s colon-targeted formulation is designed to deliver therapeutic AhR engagement directly to the colonic mucosa with the goal of minimizing the systemic AhR exposure associated with adverse effects. In preclinical studies, AT177 demonstrated robust local colonic AhR activation with markedly limited systemic exposure. AT177 is currently in IND-enabling studies, with an IND submission and Phase 1a clinical trial planned for the first half of 2027.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Azora Therapeutics, Inc.’s Item 2.02 8-K filed November 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.